AU5738700A - Enantiomers of o-desmethyl venlafaxine - Google Patents

Enantiomers of o-desmethyl venlafaxine

Info

Publication number
AU5738700A
AU5738700A AU57387/00A AU5738700A AU5738700A AU 5738700 A AU5738700 A AU 5738700A AU 57387/00 A AU57387/00 A AU 57387/00A AU 5738700 A AU5738700 A AU 5738700A AU 5738700 A AU5738700 A AU 5738700A
Authority
AU
Australia
Prior art keywords
enantiomers
desmethyl venlafaxine
desmethyl
venlafaxine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57387/00A
Inventor
Andre Alfred Asselin
John Patrick Yardley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU5738700A publication Critical patent/AU5738700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU57387/00A 1999-06-15 2000-06-14 Enantiomers of o-desmethyl venlafaxine Abandoned AU5738700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33359499A 1999-06-15 1999-06-15
US09333594 1999-06-15
PCT/US2000/016388 WO2000076955A1 (en) 1999-06-15 2000-06-14 Enantiomers of o-desmethyl venlafaxine

Publications (1)

Publication Number Publication Date
AU5738700A true AU5738700A (en) 2001-01-02

Family

ID=23303454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57387/00A Abandoned AU5738700A (en) 1999-06-15 2000-06-14 Enantiomers of o-desmethyl venlafaxine

Country Status (2)

Country Link
AU (1) AU5738700A (en)
WO (1) WO2000076955A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
DK1466889T3 (en) 1999-04-06 2008-09-08 Sepracor Inc O-desmethylvenlafaxine succinate
ATE369330T1 (en) 2001-02-12 2007-08-15 Wyeth Corp O-DESMETHYL-VENLAFAXINE SUCCINATE SALT
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
JP4445853B2 (en) 2002-06-10 2010-04-07 ワイス エルエルシー Novel O-desmethylvenlafaxine formate
BRPI0507372A (en) * 2004-02-06 2007-07-10 Wyeth Corp o-desmethylvenlafaxine (odv) multiparticulate formulation, methods for treating depression in a patient in need thereof and for reducing the gastrointestinal side effects of venlafaxine in a patient, modified multiparticulate release formulation, method for reducing side effects odv in a patient, modified-release venlafaxine product, methods to reduce gastrointestinal side effects associated with venlafaxine treatment, and to release odv in a pediatric or geriatric patient, odv and / or succinate multiparticulate formulations delayed release of odv formate or succinate, use of a formulation, and pharmaceutical package
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
EP1904040A2 (en) * 2005-07-15 2008-04-02 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
BRPI0807604A2 (en) * 2007-02-21 2014-07-22 Sepracor Inc COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATING, PREVENTING OR CONTROLING DEPRESSION, PAIN, ANXIETY, AND DISCOUNT
EP2142183A2 (en) * 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
NZ585368A (en) 2007-10-26 2012-07-27 Generics Uk Ltd Process for preparing o-desmethylvenlafaxine
EP2252573A2 (en) * 2008-02-14 2010-11-24 Egis Gyógyszergyár Nyilvánosan Müködö New polymorph and amorphous forms of desvenlafaxine fumarate
EP2119696A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2119695A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
CN101716168B (en) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 Medicinal composition containing salt of desmethylvenlafaxine and method for preparing same
CZ301820B6 (en) 2009-02-06 2010-06-30 Zentiva, K.S. Novel salts of desvenlafaxine and process of their preparation
CN106995376A (en) * 2017-04-21 2017-08-01 上海华源医药科技发展有限公司 A kind of industrialized producing technology of desmethylvenlafaxine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same

Also Published As

Publication number Publication date
WO2000076955A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AU5738700A (en) Enantiomers of o-desmethyl venlafaxine
AUPP812199A0 (en) Headgear
AU2003255982A1 (en) Preparation of microcapsules
AU3886000A (en) Synthesis of 1,2,3,4-tetrahydroxybenzenes and 1,2,3-trihydroxybenzenes using myo-inositol-1-phosphate synthase and myo-inositol 2-dehydrogenase
AUPQ253199A0 (en) Non-prostanoid prostaglandin I2-agonist
AU2003226752A1 (en) Venlafaxine base
AU7421100A (en) Microcapsules
AU6225600A (en) Centering sectional shoe assembly
AU5719500A (en) Applicator assembly
AU3006800A (en) Efficient carbamate synthesis
AU3356100A (en) Putter head assembly
AU2002322326A1 (en) Tolterodine metabolites
AU7627200A (en) Activation of peptide prodrugs by hk2
AU5613600A (en) Enantiomers of n-desmethyl venlafaxine
AU1601801A (en) Methods of preparing crna
AU1720501A (en) Methods of producing novel enzymes
PL355171A1 (en) Ethers of o-desmethyl venlafaxine
AU2002333500A1 (en) Reproduction of ribonucleic acids
AU2629599A (en) Purification of tramadol
AU2668201A (en) Method for the production of optically active cyanohydrins using r-oxynitrilase
AU2001233715A1 (en) Dermo- and gastro-specific sphingolipid activator
AU2002308926A1 (en) The method of preparing of n-n-alkyl benzoyl-2-sulfonylendoimine
AU2002228618A1 (en) Haplotypes of the lipe gene
AU1063300A (en) Process for the production of trifluoromethyltropanone cyanohydrin
AU2001257056A1 (en) Haplotypes of the mpl gene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase